about
Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion.Peptide inhibitors of dengue virus and West Nile virus infectivityRole of Endocytosis and Low pH in Murine Hepatitis Virus Strain A59 Cell EntryProgress on the development of therapeutics against West Nile virusStructural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complexBroad Distribution of Energetically Important Contacts across an Extended Protein InterfaceBroadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Successful identification of novel agents to control infectious diseases from screening mixture-based peptide combinatorial libraries in complex cell-based bioassays.Receptor-independent spread of a highly neurotropic murine coronavirus JHMV strain from initially infected microglial cells in mixed neural culturesAntibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.Novel compounds in preclinical/early clinical development for the treatment of HIV infections.Soluble receptor potentiates receptor-independent infection by murine coronavirus.Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 bindingReceptor-induced conformational changes of murine coronavirus spike protein.Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitorsN-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike proteinRational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incAn antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.New anti-HIV agents and targets.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesKinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entryThe next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Development of effective therapies against West Nile virus infection.Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.Retrovirus entry by endocytosis and cathepsin proteases.Herb-target interaction network analysis helps to disclose molecular mechanism of traditional Chinese medicine.Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41.CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptorHuman immunodeficiency virus type 1 spinoculation enhances infection through virus binding.Functional importance of the coiled-coil of the Ebola virus glycoprotein.Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.The synthetic peptide P-197 inhibits human T-cell leukemia virus type 1 envelope-mediated syncytium formation by a mechanism that is independent of Hsc70.Chimeric nectin1-poliovirus receptor molecules identify a nectin1 region functional in herpes simplex virus entry.Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.
P2860
Q24538786-E2B1D3F2-3BFB-467D-A920-680DD25A8B5DQ24813811-AAB3A04A-C67E-4C85-827F-E1534669A5CDQ27481481-85D07317-391B-49CE-AB9A-CDF4CE73E2C5Q27489893-8FC9678F-7829-479D-82DB-F05BF960AFE7Q27635422-916726DE-B757-43DC-8848-E5158B74CB0EQ27637675-C8B691BA-9D6D-4D26-BD4A-13CF5A7D8F9DQ27666255-DE58AA2F-1CB7-40D7-B011-C7674A8A0748Q30706865-AA698212-8BEC-4F0F-8FFF-160BF24F3A19Q30937880-AD9E50A6-BA4D-46AF-B941-832564AE923EQ33780607-29284414-0D58-4DFE-8E50-8D98B62ABC13Q33781344-7DB7023E-3AD5-4B5F-A77F-52A3BFF356F7Q33836042-FACCAF8C-B07C-482C-B714-09EFCCD2343AQ33848876-0B09F41A-EC90-4209-B021-31B38FB9730EQ33853769-24D20C56-8CE8-47FD-B931-80169DBAE528Q33966254-B5F28BF7-252B-4A00-9A28-0E5515FE073EQ34329104-AE8DD241-68A8-4CE7-9C5F-79A744B914C6Q34342264-7FE0B2BA-6C7A-4D37-BADD-F34FA006911AQ34349528-7EE0736F-6B2D-47B4-9219-FB3907120CAAQ34360420-29C27A78-9529-42DE-A7FD-AE3EE989678EQ34465544-53F9090C-031B-4DCB-94F3-D4A28DFC7847Q34554080-92763CE0-4000-4AC2-841A-D766E539FDB6Q34741962-A84B7D2C-6617-474F-9151-9FFD438D4ABCQ34756124-8DEDFC44-2728-4A8B-957A-8A385AA51DF9Q34944447-11952BF1-9037-4822-9D13-ED00CE114A3CQ35032794-5CBBFA22-45D0-41DA-8611-90066BCFC8C2Q35215251-F26E7FD1-9638-4417-B086-77C5F531C189Q35857748-CB4FC78D-7623-4D31-B3AB-820509479336Q35917148-B4DB3BF1-AB8A-48F1-97D1-541BAE220A19Q36322125-F6616EC0-FF40-4222-8CD2-1C5A451BF060Q36364955-71C04958-DEDA-475A-B35A-D6765680C672Q36469011-D9557D8E-39ED-40C6-9CB2-DAA9D144290BQ37408417-2BE0B2CE-5C4F-495F-9F11-617C9B211EBBQ37422890-AE5981B4-E13E-4AAC-8636-E63E3FA3E0EAQ37730009-F2944D21-E8D0-4E85-93F9-F7CE004E64DBQ39539552-23EAD131-7E3A-4A96-A066-53015F45A171Q39539619-DEB0DA6C-5E42-4CBE-9B09-A26B95594E4DQ39593524-26F17AF5-5319-46B9-9FFB-337ACAF46FE6Q39604783-14F37ABB-E5F2-4525-97F3-47FA5C6EDADCQ39606740-71FB57C5-BC37-4E42-8E2A-27EDF6267802Q40008331-FF3C918C-591C-4BE8-87E8-D0FF3661AC4E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
HIV-1 entry inhibitors in the side pocket.
@ast
HIV-1 entry inhibitors in the side pocket.
@en
type
label
HIV-1 entry inhibitors in the side pocket.
@ast
HIV-1 entry inhibitors in the side pocket.
@en
prefLabel
HIV-1 entry inhibitors in the side pocket.
@ast
HIV-1 entry inhibitors in the side pocket.
@en
P1433
P1476
HIV-1 entry inhibitors in the side pocket.
@en
P2093
Sodroski JG
P304
P356
10.1016/S0092-8674(00)81655-4
P407
P577
1999-10-01T00:00:00Z